Cytek Biosciences, Inc. Form 8-K Summary
Business context and reporting period
Cytek Biosciences, Inc. filed a Form 8-K reporting a board governance event effective December 31, 2021. The company is incorporated in Delaware, trades under the symbol CTKB on the Nasdaq Global Select Market, and identified itself as an emerging growth company.
Key financial metrics and liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material changes versus the prior comparable period
- The authorized number of directors increased from six to seven.
- Dr. Vera Imper was appointed as a Class II independent director to fill the newly created position. Her term is scheduled to expire at the 2023 Annual Meeting of Stockholders, subject to earlier departure.
Compensation, outlook, and unusual items
- Dr. Imper will receive a $40,000 annual cash retainer under the company’s non-employee director compensation policy.
- On appointment, she received a nonstatutory stock option covering 28,598 shares, with an exercise price of $16.32 per share and a stated equity value of $300,000. The option vests monthly over three years, subject to continued service.
- She is also scheduled to receive a $160,000 annual equity grant at the 2022 Annual Meeting. The grant is expected to be a nonstatutory stock option, with share count and exercise price determined on the grant date; it will vest after one year, subject to continued service.
- The company entered into its standard director indemnification agreement with Dr. Imper.
- The filing states that there are no arrangements or understandings relating to her selection, no family relationships requiring disclosure, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor verification points
- Verify the effective date and filing date. The signature block states “January 6, 2021,” which appears inconsistent with the December 31, 2021 event and may be a filing-year typographical error.
- Verify the final terms, valuation, and accounting treatment of the 28,598-share director option.
- Monitor the 2022 Annual Meeting for the additional $160,000 equity grant and its final share count and exercise price.
- Review subsequent filings for changes in board composition, director compensation, or option vesting status.